Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 6, pp 1502–1511 | Cite as

Use of Breast Imaging After Treatment for Locoregional Breast Cancer (AFT-01)

  • Taiwo Adesoye
  • Jessica R. Schumacher
  • Heather B. Neuman
  • Stephen Edge
  • Daniel McKellar
  • David P. Winchester
  • Amanda B. Francescatti
  • Caprice C. Greenberg
  • For the Alliance ACS-CRP CCDR Breast Cancer Surveillance Working Group
Breast Oncology

Abstract

Background

Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations.

Methods

A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection. Imaging and recurrence data were abstracted from patients 90 days after surgery to 5 years after diagnosis. Factors associated with lack of imaging were assessed using multivariable repeated measures logistic regression with generalized estimating equations. Patients were censored for death, bilateral mastectomy, new cancer, and recurrence.

Results

Of 9835 patients, 9622, 8702, 8021, and 7457 patients were eligible for imaging at surveillance years 1 through 4 respectively. Annual receipt of breast imaging declined from year 1 (69.5%) to year 4 (61.0%), and breast MRI rates decreased from 12.5 to 5.8%. Lack of imaging was associated with age 80 years or older and age younger than 50 years, black race, public or no insurance versus private insurance, greater comorbidity, larger node-positive hormone receptor-negative tumor, excision alone or mastectomy, and no chemotherapy (p < 0.005). Receipt of breast MRI was associated with age younger than 50 years, white race, higher education, private insurance, mastectomy, chemotherapy, care at a teaching/research facility, and MRI 12 months before diagnosis (p < 0.05).

Conclusion

Under-utilization of mammography after breast cancer treatment is associated with sociodemographic and clinical factors, not institutional characteristics. Effective interventions are needed to increase surveillance mammography for at-risk populations.

ClinicalTrials.gov Identifier: NCT02171078.

Notes

Acknowledgments

The research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (CE-1304-6543) and National Cancer Institute at the National Institutes of Health (NIH) grant number U10CA180821 to the Alliance for Clinical Trials in Oncology. Further funding came from the Building Interdisciplinary Research Careers in Women’s Health Scholar Program and University of Wisconsin Carbone Comprehensive Cancer Center Academic Oncologist Training Program (Neuman, NIH K12 HD055894, 5K12CA087718), and the National Cancer Institute funded Surgical Oncology Research Training Program (Adesoye, T32 CA090217).

Disclaimer

The data used in the study are derived from a de-identified National Cancer Database file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methods used or the conclusions drawn from these data by the investigator. Furthermore, the contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of PCORI or NIH. All statements in this publication, including its findings, are solely those of the authors and do not necessarily represent the views of NIH or PCORI, its Board of Governors or Methodology Committee.

References

  1. 1.
    Surveillance epidemiology and end results (SEER). SEER stat fact sheets: breast cancer, 2013. https://seer.cancer.gov/statfacts/html/breast.html .
  2. 2.
    Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment. American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Oncology NCPGi. Breast cancer screening and diagnosis, Version 1.2016. 2016. Retrieved 2 Feb 2017 at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  4. 4.
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International breast cancer study group trials I to V. J Clin Oncol. 2016;34:927–35.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Regan MM, Neven P, Giobbie-Hurder A, et al. Evaluating letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12:1101–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24:85–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25:1074–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Field TS, Doubeni C, Fox MP, et al. Under-utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008;23:158–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Lash TL, Fox MP, Buist DSM, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol. 2007;25:3001–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Buist DSM, Bosco JLF, Silliman RA, et al. Long-term surveillance mammography and mortality in older women with a history of early-stage invasive breast cancer. Breast Cancer Res Treat. 2013.  https://doi.org/10.1007/s10549-013-2720-x.Google Scholar
  13. 13.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Commission on cancer. Facility oncology registry data standards. Retrieved 4 May 2016 at https://www.facs.org/~/media/files/quality programs/cancer/ncdb/fords 2016.ashx.
  15. 15.
    Nurgalieva ZZ, Franzini L, Morgan R, Vernon SW, Liu CC, Du XL. Surveillance mammography use after treatment of primary breast cancer and racial disparities in survival. Med Oncol. 2013;30:691.CrossRefPubMedGoogle Scholar
  16. 16.
    Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care. 2001;39:945–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111:489–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009;20:1505–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Neuman HB, Schumacher JR, Francescatti AB, et al. Utility of clinical breast exams in detecting local-regional breast events after breast conservation in women with a personal history of high-risk breast cancer. Ann Surg Oncol. 2016;23:3385–91.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Parmar AD, Sheffield KM, Vargas GM, Han Y, Chao C, Riall TS. Quality of post-treatment surveillance of early-stage breast cancer in Texas. Surgery. 2013;154:214–25.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schapira MM, McAuliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care. 2000;38:281–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Keating NL, Landrum MB, Meara E, Ganz PA, Guadagnoli E. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? JNCI J Natl Cancer Institute. 2005;97:257–64.CrossRefGoogle Scholar
  23. 23.
    Legg JS, Fauber TL, Ozcan YA. The influence of previous breast cancer upon mammography utilization. Women’s Health Issues. 2003;13:62–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Sabatino SA, Thompson TD, Richardson LC, Miller J. Health insurance and other factors associated with mammography surveillance among breast cancer survivors: results from a national survey. Med Care. 2012;50:270–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Snyder CF, Frick KD, Peairs KS, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24:469–74.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    26. Thewes B, Lebel S, Seguin Leclair C, Butow P. A qualitative exploration of fear of cancer recurrence (FCR) amongst Australian and Canadian breast cancer survivors. Support Care Cancer 2016;24:2269–76.CrossRefGoogle Scholar
  27. 27.
    Buist DSM, Abraham LA, Barlow WE, et al. Diagnosis of second breast cancer events after initial diagnosis of early-stage breast cancer. Breast Cancer Res Treat. 2010;124:863–73.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women. J Am Coll Surg. 2008;206:1193–203.CrossRefPubMedGoogle Scholar
  29. 29.
    Bollet MA, Sigal-Zafrani B, Mazeau V, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (&lt;40 years) women treated with breast-conserving surgery first. Radiother Oncol. 2007;82:272–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Wirtz HS, Boudreau DM, Gralow JR, et al. Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. Breast Cancer Res Treat. 2014;143:541–50.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Doubeni CA, Field TS, Ulcickas Yood M, et al. Patterns and predictors of mammography utilization among breast cancer survivors. Cancer. 2006;106:2482–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Etim AE-EP, Schellhase KG, Sparapani R, Nattinger AB. Effect of model of care delivery on mammography use among elderly breast cancer survivors. Breast Cancer Res Treat. 2006;96:293–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prevent. 2006;30:52–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Saslow D, Boetes C, Burke W, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89.CrossRefPubMedGoogle Scholar
  36. 36.
    Panageas KS, Sima CS, Liberman L, Schrag D. Use of high-technology imaging for surveillance of early-stage breast cancer. Breast Cancer Res Treat. 2012;131:663–70.CrossRefPubMedGoogle Scholar
  37. 37.
    Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol. 2008;26:703–11.CrossRefPubMedGoogle Scholar
  38. 38.
    Mameri CS, Kemp C, Goldman SM, Sobral LA, Ajzen S. Impact of breast MRI on surgical treatment, axillary approach, and systemic therapy for breast cancer. Breast J. 2008;14:236–44.CrossRefPubMedGoogle Scholar
  39. 39.
    DeMartini W, Lehman C, Partridge S. Breast MRI for Cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol. 2008;15:408–16.CrossRefPubMedGoogle Scholar
  40. 40.
    Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol. 2003;181:619–26.CrossRefPubMedGoogle Scholar
  41. 41.
    Hillman BJ, Goldsmith JC. The uncritical use of high-tech medical imaging. N Engl J Med. 2010;363:4–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Brennan S, Liberman L, Dershaw DD, Morris E. Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol. 2010;195:510–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Gorechlad JW, McCabe EB, Higgins JH, et al. Screening for recurrences in patients treated with breast-conserving surgery: is there a role for MRI? Ann Surg Oncol. 2008;15:1703–9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Taiwo Adesoye
    • 1
  • Jessica R. Schumacher
    • 1
  • Heather B. Neuman
    • 1
    • 2
  • Stephen Edge
    • 3
  • Daniel McKellar
    • 4
  • David P. Winchester
    • 4
  • Amanda B. Francescatti
    • 4
  • Caprice C. Greenberg
    • 1
    • 2
  • For the Alliance ACS-CRP CCDR Breast Cancer Surveillance Working Group
  1. 1.Wisconsin Surgical Outcomes Research Program, Department of SurgeryUniversity of Wisconsin-Madison School of Medicine and Public HealthMadisonUSA
  2. 2.University of Wisconsin Carbone Cancer CenterUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  3. 3.Roswell Park Cancer InstituteBuffaloUSA
  4. 4.American College of SurgeonsCommission On CancerChicagoUSA

Personalised recommendations